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Summary
Colorectal cancer (CRC) is the most common cancer in Europe and the leading 
cause of death. A combination of therapy with targeted agents and the knowledge of 
many biomarkers is significantly increasing to better guide the selection of treatment. 
Biomarkers that are currently used as predictive and prognostic, as well as factors for 
therapy selection, are described in this overview. It refers to microsatellite instability 
(MSI), RAS-family of oncogenes, BRAF, TP53, Ki-67, Oncotype DX_, phosphatidylinosi-
tol 3-kinase (PI3K)/AKT, 18q LOH, and CpG island methylator phenotype. 
Only a few biomarkers are currently used and in routine reported by pathologists. 
Future studies need to consider the combination of markers, standardising protocols 
and, if possible, simple and standardised assays for the detection of molecular markers.
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INTRODUCTION
Colorectal cancer (CRC) is the most commonly diagnosed cancer in Eu-
rope and one of the leading causes of cancer death worldwide [1,2]. In 2008, 
436,000 new cases of CRC were diagnosed in Europe and it was responsi-
ble for 212,000 (12.2%) deaths representing the second most common cau-
se of cancer death after lung cancer (19.9%) [1]. In Croatia, combined, colon, 
rectum, rectosigmoid and anal cancers represented 15% in the male and 13% 
in the female cancer incidence in 2011 [3]. 
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In the past years treatment and outcome of early and advanced disease 
has steadily improved. Currently, a broad variety of trials and retrospective 
analyses gave further insights into clinical questions like selection and du-
ration of treatment, combinations with targeted agents and also knowledge 
of prognostic as well as predictive biomarkers is significantly increasing to 
better guide selection of treatment.
Therefore pathology report is becoming more complex and in the field of 
newfound and offered biomarkers it is becoming hard to identify and stan-
dardize those with truly predictive and prognostic value.
There are some factors definitively proven to be of prognostic importance 
based on evidence from multiple published trials and generally used in pati-
ent management. These are: the local extent of tumor assessed pathologically 
(the pT category ofthe TNM staging system of the American Joint Committee 
on Cancer and the Union Internationale Contre le Cancer [AJCC/UICC]); re-
gional lymph node metastasis (the pN category of theTNM staging system); 
blood or lymphatic vessel invasion; residual tumor following surgery with 
curative intent (the R classification of the AJCC/UICC staging system), espe-
cially positive surgical margins [4]. 
Some factors biologically and clinically shown to have prognostic value 
for outcome and/or predictive value for therapy are also reported by patho-
logist, although it remains to be validated in comprehensive studies. It inclu-
des tumor grade, radial margin status and residual tumor in the resection 
specimen following neoadjuvant therapy (the ypTNM category of the TNM 
staging system) [4].
Factors shown to be promising in multiple studies are histologic type, 
histologic features associated with microsatellite instability (MSI) (ie, host 
lymphoid response to tumor and medullary or mucinous histologic type), 
high degree of MSI (MSI-H), loss of heterozygosity at 18q (DCC gene allelic 
loss), tumor border configuration (infiltrating vs pushing border), DNA con-
tent and all other molecular markers, perineural invasion, microvessel den-
sity, tumor cell–associated proteins or carbohydrates, peritumoral fibrosis, 
peritumoral inflammatory response, focal neuroendocrine differentiation, 
nuclear organizing regions and proliferation indices [4,5].
In recent years, colorectal cancer (CRC) has been divided into different 
subgroups with distinct precursor lesions, pathways of carcinogenesis, mor-
phological, and molecular characteristics [6]. In spite of a tremendous amou-
nt of available literature on biomarkers only a few are nowadays used in da-
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ily clinical practice, such as KRAS, BRAF, MSI and the Oncotype DX_ Colon 
Cancer Assay [7]. 
BIOMARKERS
Microsatellite instability
There are two forms of genomic instability that reflect different genetic 
pathways of tumorigenesis. One refers to a clonal change in the number of 
repeated DNA nucleotide units in microsatellites caused by deletions or in-
sertions, and appears in tumors with deficient mismatch repair (MMR) [8]. 
The biochemical basis of this phenotype is explained by strand-specific 
mismatch repair defects and linked to germline mutations of the MMR gene 
hMSH2 and hMLH1. MSI phenotype is also found in Lynch Syndrome as 
mutations in PMS2 and hMSH6. If there is a clinical suspicion of Lynch Syn-
drome (Bethesda Guidelines), MSI testing with molecular screening and/or 
immunohistochemistry is recommended by the ESMO Consensus [9].
Different mechanism causes the sporadic type of MSI to develop in CRC 
and it is associated with hMLH1 promoter hypermethylation and lack of 
hMLH1 expression and subsequently loss of mismatch repair system func-
tion. This sporadic type of MSI could be investigated through testing for a 
BRAF V600E mutation that is strongly associated with a sporadic origin or by 
analysis of hMLH1 promoter hypermethylation [8,10]. 
It has been shown that MSI CRC is associated with a better prognosis 
than non-MSI CRC, but appears to be more pronounced for Lynch Syndrome 
[8,11,12].  MSI testing in molecular pathology laboratories is becoming incre-
asingly available, but requires expertise and experience in testing and inter-
pretation. Nowadays, immunohistochemistry (IHC) shows high sensitivity 
and specificity in detecting MSI and could therefore offer a relatively cheap, 
easy to perform and universally available test for MSI, instead of a more com-
plex polymerase chain reaction (PCR)-based MSI test [13,14].
KRAS
The RAS-family of oncogenes consists of three members involved in tu-
mor development, KRAS, HRAS and NRAS. Active KRAS mutations are fo-
und in 35–42% of CRCs and are thought to occur early in CRC carcinogenesis 
[15]. KRAS is part of the EGFR-signaling pathway downstream to EGFR, a 
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receptor tyrosine kinase which is activated through extracellular ligand bin-
ding. Activation of the pathway ultimately leads to the modulation of angi-
ogenesis, cell migration, proliferation, cell adhesion, metastasis formation, 
and survival [16, 17]. Differences in KRAS mutations at codon 12 and 13 may 
result in different biological and functional consequences that could influen-
ce the prognosis of CRC. Initially, KRAS was found to be a strong prognostic 
factor in CRC, but this finding was later restricted to a codon 12 mutation, 
leading to a glycine to valine substitution (G12V).
American Society of Clinical Oncology recommends that all patients 
with metastatic colorectal carcinoma who are candidates for anti-EGFR anti-
body therapy should have their tumor tested for KRAS mutations. If KRAS 
mutation in codon 12 or 13 is detected, then patients should not receive an-
ti-EGFR antibody therapy as part of their treatment [18,19]. The attempt to 
predict response to EGFR treatment by assessing EGFR expression by immu-
nohistochemistry  in analogy to HER2/new in breast cancer turned out to be 
unsuccessful [6]. Mutation of the KRAS gene results in a constitutively active 
KRAS protein and mitogen activated protein kinase (MAPK) pathway signa-
ling independent from EGFR [6].
In general, KRAS mutational analyses concentrate on mutations in codon 
12 and 13 with commercially available kits such as the ‘Therascreen KRAS 
Mutation Test kit’, which make up for 96% of all observed mutations. Other 
activating mutations have been identified in these codons and, additionally, 
in codon 61 and 146 of the KRAS gene.
Approximately 1% of tumors with wild type at codons 12 and 13 will 
have mutations in codon 146 and an additional 7% of these will be mutated 
in codon 61 (6,8,18,19). These mutations may very well predict resistance to 
anti-EGFR treatment as may mutations of the Neuroblastoma RAS viral on-
cogene homolog (NRAS) gene. It remains to be seen, whether expanded mu-
tational analyses of KRAS and NRAS adds substantial additional predictive 
value [6,8].
BRAF
The BRAF gene encodes a serine/threonine protein kinase belonging to 
the RAS-RAF-MEK-ERK kinase pathway regulated by KRAS protein activity 
and involved in CRC development. Nearly all oncogenic transformations of 
BRAF are the V600E mutations (8,20,21). The frequency of BRAF mutations 
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in CRC decreases with advancing UICC stage, approximately 8% of all CRC 
carry a BRAF mutation which is mutually exclusive to KRAS mutations 
[5,8,22].
After being primarily discussed as a potent predictive marker for resi-
stance to anti-EGFR treatment, BRAF mutation has meanwhile been reported 
as a marker for poor prognosis in CRC in a number of retrospective analyses 
of large clinical trials.
The prognostic value of BRAF mutation is obviously influenced by the 
MSI status. In fact, patients with BRAF mutation and MSI had a favorable 
prognosis when compared with microsatellite stabile( MSS)/ BRAF wild-ty-
pe patients [5,8,22,23].
Immunohistochemistry (IHC) can be used in detecting BRAF mutation; it 
shows high sensitivity and specificity for BRAF V600E mutation.
Other potential biomarkers 
TP53 is a tumor suppressor gene on the short arm of chromosome 17, en-
coding a protein important in regulating cell division. It is aborting growth 
of potentially malignant cells. Mutations of the TP53 gene are detected in up 
to 85% of CRCs, usually occurring during the adenoma to adenocarcinoma 
transition (24,25,26). Lack of consensus on antibodies and scoring methods 
in immunohistochemical staining, lack of correlation between immunohis-
tochemical overexpression and clinical data and discrepancies between im-
munohistochemistry and mutation analysis are responsible for conflicting 
results and are therefore important reasons for not justifying the use of TP53 
in clinical practice [8,26,27]. 
Proliferation and ability to evade apoptosis is one of the most important 
attributes tumor cells must acquire for tumorigenesis. Ki-67 is used to deter-
mine proliferation in tumor cells but lack of uniformity in methodological 
approach and variations in the interpretation and reporting of pathologic 
findings are currently the most problematic issues associated with this fac-
tor. Further research should focus on combined analysis of proliferation and 
apoptosis, as a balance might exist between these two hallmarks of cancer 
[6,8,28-30].
Genomic signatures potentially have a high prognostic value and some 
are already in use in clinical practice, like Oncotype DX_. Other genomic 
signatures need to be validated before introducing them in clinical practice, 
preferably using tissues from randomized clinical trials [6,8,31-33]. 
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Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway has 
been associated with the development of a human CRC, when stratified by 
KRAS status, a worse colon cancer-specific mortality associated with a PIK-
3CA mutation was only found in KRAS wildtype tumors [8,34].
The prognostic value of 18q LOH also remains unclear and validation is 
necessary to draw further conclusions [35].
The existence of a new pathway for CRC pathogenesis which involves the 
transcriptional silencing of tumor suppressor genes by hypermethylation of 
CpG islands of the promoter region of various genes is increasingly studying. 
These tumors are classified as having the CpG island methylator phenotype 
(CIMP). CIMP could be used as a prognostic marker, but further research is 
necessary to confirm and validate these data [35,36,37]. 
CONCLUSION 
Our knowledge of the process of tumorigenesis has been increasing in 
the past decades and it affects the development of new treatment modalities 
in human cancer. Only a few biomarkers are currently used and in routine 
reported by pathologist. Future studies need to consider the combination of 
markers, standardising protocols and if possible  simple, cheap, automated 
and standardized assays for the detection of molecular markers. Most impor-
tantly, results need to be validated in larger studies, followed by prospective 
trials.
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Sažetak
Kolorektalni karcinom, novi biomarkeri i uloga imunohistokemije
Kolorektalni karcinom najčešći je maligni tumor u zemljama Europe te jedan od 
vodečih uzroka smrti od raka. Kombinirana terapija s lijekovima koji djeluju ciljano 
(tzv. pametni lijekovi) te sve više novih saznanja i novootkrivenih biomarkera koje tu-
mor eksprimira značajno je povećala mogućnost selektivne terapije.  Biomarkeri koji se 
trenutno sve više koriste kao prognostički i prediktivni, kao i oni koji su važni za izbor 
terapije opisani su u ovom pregledu. Među spomenute se najčešće ubraja mikrosate-
litska nestabilnost zbog pogreške u popravku gena, RAS-obitelj onkogena, BRAF, TP53, 
Ki-67, Onkotip DX, fosfatidilinozitol-3 kinaza (PI3K)/AKT, 18q LOH i CpG metilacijski 
fenotip. Trenutno je u široj upotrebi svega nekoliko markera te se rutinski spominju u 
patološkom izvještaju. 
Buduće studije bi centar istraživanja trebale usmjeriti prema kombinacijama različi-
tih markera, uspostavi standardiziranih protokola te jednostavnih i dostupnih analiza za 
otkrivanje ekspresije molekularnih markera.
Ključne riječi: kolorektalni karcinom; biomarker; mikrosatellitska nestabilnost; 
KRAS; BRAF.
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